688185
vs
S
Shanghai Composite
688185
Over the past 12 months, CanSino Biologics Inc has underperformed Shanghai Composite, delivering a return of -2% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688185 vs Shanghai Composite
Performance Gap
688185 vs Shanghai Composite
Performance By Year
688185 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CanSino Biologics Inc
Glance View
CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.